This is the Mexican Laboratory that will package the Oxford-AstraZeneca Vaccine for Latin America

Thanks to the strategy to distribute the vaccine in Latin America, the product manufactured in the Argentine mAbxience laboratory was transferred to the Mexican facilities of Liomont, the laboratory that will be in charge of completing the process of stabilization, manufacturing and packaging of medicine, due to its relevance in the manufacture of medicines worldwide.

This pharmaceutical company was founded in 1938 and currently has one of the most modern plants in Latin America, which It was inaugurated in March 2019 and is located in the municipality of Ocoyoacac, State of Mexico. It is worth mentioning that the current spokesperson for the pandemic in the country, the Undersecretary of Prevention and Health Promotion, was present at that event, Hugo Lopez-Gatell.

Inside the plant are produced injectable medications, vaccines, and even rheumatoid arthritis therapies. It has isolator technology, which, according to the pharmaceutical company, guarantee the sterility of the products they develop.

Liomont has been highlighted by governmental authorities as a laboratory “with high sense of social responsibility, worried and occupied by the welfare of society”. Furthermore, it is a An important source of employment in the sector for the country, as it employs 1,500 people.

Carlos Slim Domit pointed out which laboratories will be in charge of producing the vaccine in Latin America. 

Have a production capacity of 120,000,000 units per year and can develop prescription and over-the-counter products. Its relevance is such in the pharmaceutical market that ranks number eight nationally today.

In May 2020, together with other laboratories that are part of the National Chamber of the Pharmaceutical Industry (Canifarma) donated 88 artificial respirators for the care of serious cases of COVID-19 to various public health institutions, such as the National Institute of Respiratory Diseases (INER), the Salvador Zubirán National Institute of Medical Sciences and Nutrition and the Mexican Institute of Social Security (IMSS), among others.

The Secretary of Foreign Relations, Marcelo Ebrard, announced the details of the agreement between the government of Mexico, Argentina, the pharmaceutical company AstraZeneca and the Slim Foundation for produce and distribute the vaccine developed by the University of Oxford.

The current estimate for production would range from 150 to 250 million vaccines. 

“The purpose of AstraZeneca, the Slim Foundation and the University of Oxford is not profit, it is guarantee that Latin America has access to this vaccine and that same is the motivation of the governments of Mexico and Argentina“, Commented the chancellor to later detail that the current estimate for production would range from 150 to 250 million vaccines.

He also highlighted the fact that from this agreement, the Times for the region to obtain a vaccine will be significantly reduced, because if before it was thought that the medicine could take more than a year to reach the population, “I know I would advance six or seven months and that difference is all for the economy and health”.

In this sense, he highlighted that the participation of the Slim Foundation will be of great relevance to guarantee the start of production “in a timely manner”, while the governments will be responsible for the distribution and administration of vaccines with different countries.